Income Statement (TTM)
Canntab Therapeutics Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 11-30 |
2021 02-28 |
2021 08-31 |
2021 11-30 |
2022 02-28 |
2022 05-31 |
2022 08-31 |
2022 11-30 |
2023 02-28 |
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | -0 | -1 | 0 | 0 | 0 | 0 |
| Change (%) | 123.12 | -95.91 | -600.24 | 241.49 | -149.76 | 1.36 | -51.54 | -49.01 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 0 | 1 | 0 | 0 | -0 | 1 | 1 | 1 | 1 |
| Change (%) | 101.36 | -50.34 | -71.51 | -324.62 | -772.39 | -0.89 | 0.87 | 13.70 | |
| % of Revenue | 75.76 | 68.37 | 829.74 | -47.26 | 31.09 | 420.09 | 410.74 | 854.95 | 1,906.30 |
| Gross Operating Profit | 0 | 0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 |
| Change (%) | 191.09 | -194.41 | 0.95 | 59.80 | 131.13 | -1.60 | 17.73 | 22.00 | |
| % of Revenue | 24.24 | 31.63 | -729.74 | 147.26 | 68.91 | -320.09 | -310.74 | -754.95 | -1,806.30 |
| SG&A | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 |
| Change (%) | 2.75 | -1.43 | 8.27 | 0.43 | -2.92 | -12.25 | -18.79 | -27.20 | |
| % of Revenue | 699.55 | 322.16 | 7,760.26 | -1,679.53 | -493.93 | 963.68 | 834.27 | 1,398.17 | 1,996.11 |
| R&D | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -85.91 | 553.59 | -20.76 | 165.04 | 3.16 | -8.06 | -8.68 | -46.81 | |
| % of Revenue | 27.19 | 1.72 | 274.21 | -43.44 | -33.71 | 69.89 | 63.40 | 119.47 | 124.61 |
| OpEx | 3 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 |
| Change (%) | 10.98 | -0.64 | 0.87 | -4.62 | 36.21 | -9.23 | -9.44 | -11.85 | |
| % of Revenue | 896.88 | 446.12 | 10,832.62 | -2,184.36 | -610.10 | 1,670.01 | 1,495.54 | 2,794.79 | 4,831.09 |
| Operating Income | -3 | -3 | -4 | -4 | -4 | -5 | -4 | -4 | -3 |
| Change (%) | -3.09 | 26.89 | 6.47 | 6.15 | 10.02 | -9.90 | -6.43 | -10.48 | |
| % of Revenue | -796.88 | -346.12 | -10,732.62 | 2,284.36 | 710.10 | -1,570.01 | -1,395.54 | -2,694.79 | -4,731.09 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -1 |
| Change (%) | 62.85 | 334.33 | 39.17 | 14.70 | 17.22 | 16.32 | 17.07 | 7.39 | |
| % of Revenue | -11.33 | -8.27 | -877.49 | 244.13 | 82.00 | -193.16 | -221.68 | -535.55 | -1,127.87 |
| Net Income | -3 | -3 | -4 | -5 | -5 | -4 | -4 | -3 | -3 |
| Change (%) | -2.17 | 37.94 | 14.87 | -3.94 | -18.91 | -3.69 | -5.40 | -0.17 | |
| % of Revenue | -808.21 | -354.39 | -11,945.81 | 2,743.05 | 771.64 | -1,257.55 | -1,194.92 | -2,332.67 | -4,566.80 |
Source: Capital IQ
